Triiodothyronine (T3) for Heart Failure

"Enrollment in this medical trial necessitates that applicants are between the ages of 18 to 80. For those under 18, there is a separate clinical study with 22 participants; likewise, 690 individuals who exceed 65 years old have access to an alternate research opportunity."

"This scientific study is looking for 20 participants aged between 18 and 80 who have been diagnosed with heart failure. They must also meet additional requirements, including stable symptoms recognised by the NYHA classification system (II-III), having received guideline-based standard HF therapies at maximum tolerated doses for over a month, receiving metoprolol succinate for 3 or more months and being in possession of an ICD device or CRT-D implantable defibrillator for 1+ month. All volunteers must sign a consent form indicating they understand the risks involved."

"According to clinicaltrials.gov, this research opportunity is open and accepting applicants as of November 14th, 2022; the original post was uploaded on January 1st 2023."

"Affirmative, the clinical trial is accepting participants based on information hosted on clinicaltrials.gov. The scientific experiment was first published on January 1st 2023 and has been updated as recently as November 14th 2022. A total of 20 patients are needed for this study at two distinct healthcare facilities."

"This clinical trial will assess, over a timeline of Baseline, Days 1*, 2*, 3*, 4*, 5*, 6 weeks, 3 months, 6 months and 12 months intervals the number of participants with Angina, acute coronary syndrome or death in the first week. Secondary outcomes tracked include Change in 6-minute walk distance (6MWD), which entails two tests conducted at least two hours apart to determine baseline mean; Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) summary score that requires a minimum change of five points for it to be considered significant; and Change in left ventricular ejection fraction (L"